Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia

Interventions

DRUG: Decitabine
DRUG: Vorinostat
DRUG: Filgrastim (G-CSF)
DRUG: Fludarabine
DRUG: Cytarabine

Sponsor

Therapeutic Advances in Childhood Leukemia Consortium